Teresa Vitale's questions to Geron Corp (GERN) leadership • Q1 2025
Question
Teresa Vitale of Scotiabank inquired about commercial strategies to encourage physicians to switch patients from luspatercept to RYTELO sooner, and asked about the reasons for any KOL hesitation to prescribe RYTELO in earlier lines of therapy.
Answer
Jim Ziegler, Chief Commercial Officer, noted that market research shows physician awareness of RYTELO's profile drives favorable perceptions and that recent data shows 20% of use is now in first and second lines. Dr. Joseph Eid, EVP of R&D, added that data presented at ASH demonstrated imetelstat's efficacy post-luspatercept and that physician hesitancy often stems from a lack of awareness, which is overcome with education on the drug's unique mechanism.